JP-7855197-B2 - Intervertebral disc treatment agent

Inventors

• 阪上 守人
• 松本 昌也
• 長屋 昌宏
• 海渡 貴司
• 小玉 城
• 平井 宏昌

Assignees

• 株式会社ツーセル
• 国立大学法人大阪大学

Dates

Publication Date

20260508

Application Date

20220920

Claims (2)

1. It contains a scaffold-free artificial tissue in which human synovial membrane-derived mesenchymal stem cells form a three-dimensional structure. The aforementioned mesenchymal stem cells are cultured without serum and are used as a treatment for intervertebral disc disease.
2. The intervertebral disc treatment agent according to claim 1 , further comprising the extracellular matrix derived from the mesenchymal stem cells.

Description

This invention relates to a treatment agent for intervertebral discs. Intervertebral disc damage tends to have a serious impact on daily life, often accompanied by pain in the back and lower back. In recent years, regenerative medicine using cell transplantation has been applied to treat such intervertebral disc damage. As cells applicable to regenerative medicine, for example, Patent Document 1 proposes a scaffold-free, self-assembling, three-dimensional artificial tissue with tissue strength suitable for clinical application. Furthermore, Non-Patent Document 1 demonstrates the therapeutic effect of transplanting tissue regeneration material (TEC; Tissue Engineered Construct) prepared using rat adipose-derived mesenchymal stem cells according to the method described in Patent Document 1 on intervertebral disc injuries. International Publication No. 2005/012512 brochure H. Ishiguro et. al., Acta Biomaterialia 87, 118-129, 2019 This figure illustrates the evaluation of intervertebral disc height (DHI) in the example.This figure illustrates the evaluation of endplate damage score (CT score) using CT in the embodiment.This figure shows X-ray images of the surgical sites of the rat group used in the example.This figure shows the results of the DHI and CT scores evaluated in the example.This figure shows the vimentin staining results in the examples. The embodiments of the present invention are described below, but the present invention is not limited thereto. Unless otherwise specified in this specification, "A to B" indicating a numerical range means "A or greater, B or less." [Intervertebral disc treatment agent] An intervertebral disc treatment agent according to one aspect of the present invention contains a scaffold-free artificial tissue in which synovial mesenchymal stem cells have formed a three-dimensional structure. The inventors have discovered that scaffold-free artificial tissue formed from synovial mesenchymal stem cells that have formed a three-dimensional structure is effective in treating intervertebral discs. Furthermore, the inventors have found that this scaffold-free artificial tissue, formed from synovial mesenchymal stem cells that have formed a three-dimensional structure, has good engraftment at the transplant site and remains there for a long period. Therefore, an intervertebral disc treatment agent containing scaffold-free artificial tissue formed from synovial mesenchymal stem cells that have formed a three-dimensional structure exhibits excellent therapeutic efficacy and sustained therapeutic effect. Intervertebral disc therapy agents can be used to treat damaged or defective intervertebral discs. By administering these agents to the area requiring treatment, they heal the damage or defect in the intervertebral disc. Administering these agents to the damaged or defective area of the intervertebral disc promotes disc regeneration at the administration site, thereby healing the damage or defect. In intervertebral disc treatment using intervertebral disc therapy agents, the method of administering the agent is not particularly limited. Examples include transplanting the intervertebral disc therapy agent to the treatment site or injecting a solution containing the intervertebral disc therapy agent into the treatment site. The intervertebral disc therapy agent may be administered to the treatment site alone or in combination with other therapy agents. (Synovial membrane-derived mesenchymal stem cells) In this specification, "mesenchymal stem cells" refers to somatic stem cells that differentiate into tissues belonging to the mesenchyme. Furthermore, mesenchymal stem cells also include those isolated from mesenchymal stem cells with specific properties, those stimulated with cytokines or other stimuli, and those that have undergone gene transfer. For example, MUSE cells, MACC cells, and SP-1 cells are also included in the category of mesenchymal stem cells. Mesenchymal stem cells possess proliferative capacity and the ability to differentiate into osteocytes, chondrocytes, muscle cells, stromal cells, tendon cells, adipocytes, etc. Mesenchymal stem cells are known to be isolated not only from adult tissues such as bone marrow, adipocytes, synovial cells, alveolar bone, and periodontal ligament, but also from the placenta, umbilical cord, umbilical cord blood, and various fetal cells. The synovial-derived mesenchymal stem cells that form the artificial tissue contained in the intervertebral disc treatment agent are stem cells contained in the synovial membrane and are obtained from synovial tissue by known methods. Synovial-derived mesenchymal stem cells have the ability to differentiate into chondrocytes. While synovial-derived mesenchymal stem cells may be derived from the synovial membranes of non-human animals such as rats and mice, human synovial-derived mesenchymal stem cells are preferred. Human synovial-derived mesenchymal stem cells exhibit better engraftment at the treatment site